Table 3.
Interaction between miRNAs and PDCD in other non-neoplastic disorders.
| Disorder | miRNA | Animal-human | Cell lines | Targets | Pathways | Function | Ref |
|---|---|---|---|---|---|---|---|
| – | miR-21-5p | – | L02 | PDCD4, ROS, MMP, MRCC I/II | – | Upregulation of miR-21-5p by ROS through targeting PDCD4 could regulate the proliferation and apoptosis in L02 hepatocytes. | (36) |
| – | miR-28 | C57BL/6 mice | B16F10 | PD1, Foxp3+, BTLA, TIM3, IL-2, TNF-α |
– | Upregulation of miR-28 by targeting PD-1 and regulating cytokine secretion could modulate exhaustive differentiation of T cells. | (35) |
| Intervertebral Disc Degeneration (IDD) | miR-21 | 20 IDD patients and 5 healthy control | – | PDCD4, MMP-2, MMP-9 | c-Jun | Upregulation of miR-21 by regulating PDCD4 expression, enhancing phosphorylation of c-Jun protein, and activating AP-1-dependent transcription of MMP-2/9 could promote the proliferation of human degenerated NP cells. | (29) |
| Amyotrophic Lateral Sclerosis (ALS) | miR-183-5p | – | Neuro2a, NSC-34 | PDCD4, TNF-α, RIPK3, Caspase-3 |
– | Upregulation of miR-183-5p by targeting PDCD4 could enhance the survival rate of neurons under stress conditions in ALS cell lines. | (30) |
| Knee Scar Adhesion | miR-21 | Rabbit | 293T | PDCD4, PARP, Bax, Bcl-2 | – | Downregulation of miR-21 could increase fibroblast apoptosis and prevent knee scar adhesion through influencing expression of PDCD4 in vivo and in vitro. | (31) |
| Steroid−Induced Avascular Necrosis Of Femoral Head (SANFH) | miR-206 | 15 SANFH and 15 healthy control specimens | hFOB1.19, 293T | PDCD4, ALP, Bax, Bcl-2 | – | Upregulation of miR−206 by targeting PDCD4 could reduce cell viability and proliferation, and enhance apoptosis in hFOB1.19 cells. | (33) |
| Immune Thrombocytopenia (ITP) | miR-155-5p | Female CBA mice/Human: 42 patients with ITP and 30 healthy volunteers | PBMCs, 293T | PD1, PDL1, SOCS1, IL-4, IL-10, IL-17A, TGF-β1 | – | Downregulation of miR-155-5p could induce the PD1/PDL1 pathway-mediated macrophage M2 polarization and suppress ITP progression via targeting SOCS1. | (37) |
| Contrast-Induced Acute Kidney Injury (CI-AKI) | miR-21 | – | HK-2, 293T |
PDCD4, Bcl-2, Bax | – | Upregulation of miR-21 by targeting PDCD4 could suppress HK-2 cell apoptosis. | (38) |
| Type 1 Diabetes (T1D) | miR-424-5 | Male SD rats | – | PD-1, T-bet, CXCR3, STING, IGF-1, SHP2, Rheb, Rictor | mTORC | Upregulation of miR-424-5p by targeting PD-1 signaling molecules could result in the immune response in T1D. | (34) |
| Congenital Hypothyroidism (CH) | miR-124-3p | Pregnant SD rats | – | PDCD6, PARP, Caspase-3, Bcl−2, Bax | – | Upregulation of miR-124-3p by targeting PDCD6 could suppress the progression of CH. | (39) |
| Alzheimer’s Disease (AD) | miR-21 | – | SH-SY5Y | PDCD4, amyloid-β, GSK-3β, Bcl-2, Bax |
PI3K/AKT | Upregulation of miR-21 by targeting the PDCD4/PI3K/AKT/GSK-3β pathway could reduce apoptosis in SH-SY5Y cells. | (40) |
| Atherosclerosis | miR-16 | ApoE-/- mice with a C57BL/6 background | RAW264.7, 293T | PDCD4, TNF-α, IL-10, IL-6, TGF-β, NF-κB, p38 |
MAPK, ERK, JNK | Upregulation of miR-16 by targeting PDCD4 could inhibit inflammatory macrophages activation in atherosclerosis through the MAPK and NF-κB pathways. | (32) |
| Cholesteatomas | miR-21 | 7 pairs of cholesteatoma and normal skin samples | – | PDCD4, IL-6R, gp130, PTEN | STAT | Upregulation of miR-21 by targeting PTEN and PDCD4 could regulate apoptosis, proliferation, invasion, and migration of Cholesteatoma. | (41) |